摘要:
This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.
摘要:
This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.
摘要:
This invention relates to a water-soluble bean-based extract including one or more isoflavone glycosides. Also shown is a method of preparing such a water-soluble bean-based extract.
摘要:
This invention relates to a water-soluble bean-based extract including one or more isoflavone glycosides. Also INCLUDED is a method of preparing such a water-soluble bean-based extract.
摘要:
This invention relates to a water-soluble soybean-based extract including one or more isoflavone glycosides. Also described is a method of preparing such a water-soluble soybean-based extract.
摘要:
This invention relates to a water-soluble bean-based extract including one or more isoflavone glycosides. Also included is a method of preparing such a water-soluble bean-based extract.
摘要:
A chimeric antigen receptor containing (i) a single chain Fv that specifically binds to stage-specific embryonic antigen 4 and (ii) an endodomain from CD3ζ or FcεRIγ. Also provided is a nucleic acid encoding the chimeric antigen receptor and an expression vector that contains the nucleic acid operably linked to a promoter that is active in T cells. Furthermore, two similar methods for treating a tumor are disclosed. The first method includes (i) obtaining T cells from a subject, (ii) transducing the T cells in vitro with an expression vector encoding a chimeric antigen receptor that contains an scFv specifically recognizing stage-specific embryonic antigen 4, (iii) expanding the transduced T cells in vitro, and (iv) infusing the expanded transduced T cells into the subject. The second method includes, in place of step (ii) above, transducing the T cells in vitro with an expression vector encoding a chimeric antigen receptor that is specific for a tumor antigen other than stage-specific embryonic antigen 4, and further requires a step of administering an antibody against stage-specific embryonic antigen 4.
摘要:
An immunogenic composition that includes a glycoconjugate containing a fusion protein composed of an immunoglobulin gamma Fc domain fused to a tumor-associated antigen, the fusion protein being cross-linked to an azido-modified stage-specific embryonic antigen 4 conjugated to diphtheria toxoid cross-reactive material 197; and α-galactosylceramide C34 or α-glucosylceramide C34. Also provided are methods for treating cancer by administering the immunogenic composition to a patient.
摘要:
There are described an anti-cancer composition and a method of treating differentiated carcinomas or melanoma, Featuring a suitable carrier and particular 2,4,6-tri(aryl or heteroaryl) thiapyrylium dyes.
摘要:
A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent that enhances T cell anti-tumor responses. Also provided is a pharmaceutical composition for treating a tumor. The pharmaceutical composition contains an anti-SSEA4 antibody or antibody fragment, an agent that enhances T cell responses, and a pharmaceutically acceptable excipient.